Pfizer on Friday said it’s delaying its FDA vaccine authorization request for children under five years old because there’s not enough data yet on the efficacy of a third dose.
The agency said an FDA advisory panel meeting, originally scheduled for next week, has been postponed.
“Cases continue to accumulate according to the study protocol and more data are being generated because rates of infection and illness remain high in children of this age, especially due to the recent Omicron surge,” Pfizer said in a statement, per The Hill.
